YUTIQ addresses a significant unmet need in the treatment of chronic non-infectious uveitis affecting the posterior segment of the eye. The uveitis treatment market is projected to grow steadily, ...

Aims To characterise the clinical features of human leucocyte antigen (HLA)-B27 + acute anterior uveitis (AAU) patients with or without ... neovascularisation of the iris and hypotony, nor was there ...

New treatment guidance has been developed to help doctors tackle uveitis—one of the leading causes of vision loss. The new ...

The patient’s presentation is consistent with bilateral non-granulomatous acute anterior uveitis. A thorough review of systems and social history should be taken in patients with acute ...

Currently, moon blindness is treated mostly with steroids applied topically or injected into the eye during a flare-up in an ...

It is believed that there are four main factors, which determine iris colour: the pigment granules within the posterior pigment epithelium, the concentration of pigment within the iris stromal ...

To describe tocilizumab (TCZ) effectiveness in 15 children with refractory non-infectious uveitis. Reported outcomes are the ...

Uveitis is uncommon in patients with multiple sclerosis (MS), but the link between the two entities is clearly established. While a common etiology or pathologic process remains unknown, shared ...

AIIMS Bhopal's Department of Ophthalmology successfully hosted the Uveitis Meet 2025, a significant super-specialty academic conference in central India, focusing on complex eye conditions, ...

Macular edema is the leading cause of visual loss in uveitic patients, and is a predictable feature of pars planitis, Behcet's and sarcoid uveitis, HLA-B27 related uveitis, and birdshot ...